Introduction
Cancers are thought to evolve from normal cells to a malignant cell population that often is highly diversified genetically and epigenetically. Most of this evolution seems to occur even before the tumor reaches a size that can be detected clinically. Genetic diversity results from mutations in genes that make the incipient cancer prone to accumulate additional mutations (e.g., mutations in p53 or possibly in p68, a co-activator of p53 (1)) and/or drive malignant growth. The diversity provides cancers with variants that can escape specific treatments (2) . Mutations in cancers regularly include non-synonymous nucleotide substitutions that result in single amino acid substitutions (AAS). These somatic mutations are the basis of truly cancer-specific antigens (also referred to as neoantigens or
neoepitopes) recognized by T cells (3).
This discovery two decades ago was soon confirmed in human cancer (4, 5) and followed by the suggestion that tumor-specific T cell antigens recognized by T cells on a cancer may be predicted by analyzing its somatic mutations, an approach referred to as 'reverse immunology' (6) . However, wide interest in targeting tumor-specific AAS only developed more recently (7, 8) following the availability of high-throughput genomic analysis and computer algorithms predicting neoepitopes.
Interest further intensified with the finding that the clinical efficacy of tumor-infiltrating T cells (TILs) (9) or immune checkpoint inhibitors (10, 11) may correlate with endogenous T cell responses to neoepitopes. Consequently, stimulation of T cells with mutant peptides is being combined with immune checkpoint inhibitors (12) that can activate and/or rescue exhausted endogenous cancer-specific T cells (13) . The success of these approaches, however, may be limited because they rely on stimulating tolerant T cells which revert to an ineffective state after transient activation (14) .
To avoid these limitations, unbiased peripheral T cells of patients can be engineered to express antigen receptors of a chosen specificity. For example, T cells expressing anti-CD19 chimeric 6 antibody receptors can eradicate advanced leukemia and lymphomas even though normal B cells are also ablated (15) . Since targeting other non-mutant self-antigens on tumors by adoptive T cell transfer caused severe toxicity and only little efficacy (16) , we engineered T cells to express TCRs recognizing a shared (or trunk) mutation to determine the conditions by which targeting a single cancer-specific point mutation eradicates a progressively growing, genetically heterogeneous cancer. To our knowledge this is the first study to show that under the right conditions, mutation-specific TCR gene therapy provides an effective, truly tumor-specific cancer treatment.
Material and Methods

Whole-exome and RNA sequencing
Genomic DNA and total RNA were extracted, DNA and RNAseq libraries were prepared, and sequenced by 150 bp paired-end reads on NextSeq 500 Desktop Sequencer or HiSeq2500 Sequencer (Illumina, San Diego, CA). Detailed information are provided in Supplementary Methods.
Read mapping and variant calling
Low-quality reads (more than 80% of bases were base quality less than 20) were excluded using FASTX toolkit (Gregory J. Hannon, Cold Spring Harbor Laboratory, NY). For whole-exome sequencing, sequence reads were mapped to the mouse reference genome mm10 using BurrowsWheeler Aligner (BWA v0.7.10 (17)). Possible PCR duplicated reads were removed (Picard v1.91, Broad Institute, Cambridge, MA), and read pairs with a mapping quality <30 and mismatches more than 5% of read length were excluded. For RNAseq, sequence reads were mapped to the mouse reference genome mm10 using STAR (18) , and possible PCR duplicated reads and reads with a mapping quality <30 were excluded. Somatic variants were called using a Fisher's exact test-based method (19) and annotated using ANNOVAR (20) . Detailed information on variant calling are provided in Supplementary Methods.
Neoepitope prediction
Binding affinity to H-2K b and H-2D b was predicted for 8-, 9-, and 10-mer peptides containing nonsynonymous variants and found to be expressed in Bulk (variant reads ≥1 in RNAseq). Amino acid sequences were analyzed by the NetMHC 3.4 server (21) and binding affinity is expressed as half maximum inhibitory concentration (IC 50 ) of the respective neoepitope.
Cells
MC57 is a methylcholanthrene-induced C57BL/6-derived fibrosarcoma (provided by Pamela Ohashi (University of Toronto, Toronto, Ontario, Canada), with permission of Hans Hengartner (University Hospital Zurich, Zurich, Switzerland)). Its transfectants MC57-SIY and MC57-mp68 were generated in our laboratory and have been described (22, 23) . 8101 originated in a UV-treated C57BL/6 mouse and was generated in our laboratory (24) . Fragments of the original 8101 tumor (1-2 mm in size) were frozen. Bulk is a primary tumor cell culture derived from approx. 20 fragments of the original 8101 tumor. The cell line Bulk-mp68 was generated using MFG-mp68-EGFP as described (23) . All tumor cell lines, RMA-S cells (see reference in (24)) and Plat-E packaging cells (see reference in (25)) were maintained in Dulbecco's modified Eagles medium supplemented with 10% fetal calf serum (FCS, Gemini Bio-Products, West Sacramento, CA). Unless otherwise indicated, cell culture reagents were purchased from Invitrogen (Life Technologies, Carlsbad, CA). Before use, tumor cell lines were authenticated by sequencing and/or co-culture with antigen-specific T cells. RMA-S and Plat-E cells were shortly passaged after thawing of the initial frozen stock to generate master cell banks. Working batches were passaged no longer than 3 months and authenticated by cellular morphology.
Generation and characterization of mp68-specific T cell clones, isolation of 1D9 TCR genes
T cell clones specific for mp68 (H-2K b :SNFVAGI) were generated by immunizing C57BL/6 mice with Bulk tumor cells using procedures previously described (26) except that IL-2 (6 IU/ml) was used instead of T cell growth factor for expansion and cloning of the T cells. Specificity of established T cell cultures was analyzed by specific lysis of RMA-S cells loaded with mp68 (SNFVFAGI) or p68 wildtype peptide (SNFVSAGI, both peptides: 7.8x10 -9 M, provided by Steven Meredith, University of Chicago, Chicago, IL) and Bulk tumor cells expressing the antigen at natural levels as described (24) .
1D9 TCR sequences were determined by 5'-RACE-PCR following manufacturer's instructions (Life Technologies): TRAV1-CAVRSDTNAYKVIF-TRAJ30, TRBV19-CASSKRLSSYEQYF-TRBJ2-7.
The 1D9 TCR was modified to form a second disulfide bond (27) and codon-optimized genes (GeneArt, Life Technologies) were integrated into MP71-PRE as described (MP71-1D9) (22) . 
Mice
TCR gene transfer
Plat-E packaging cells were transiently transfected with MP71-1D9 or MP71-2C (22) (30) . Briefly, mice were locally irradiated using an x-ray generator (PCM 1000; Pantak) at a dose of 10 Gy. Mice were shielded with a lead cover leaving the subcutaneous tumors exposed through an opening on the side. Mice were irradiated when tumors reached the size of approx. 300 mm 3 and T cells were transferred one day later.
Isolation of CD11b
+ stromal cells
Tumors were isolated, single cell suspensions were generated by enzymatic digestion and CD11b + cells were enriched using magnetic cell sorting as described (31) . Sorted cells were used for co-cultures with 1D9td or 2Ctd T cells.
T cell analysis
To analyze antigen presentation by indicated tumor and stroma cells, co-cultures were performed with 1D9td and 2Ctd T cells as described (31) . T cell activation was assessed by measuring IFN-γ content of 24 h co-culture supernatants by enzyme-linked immunosorbent assay (ELISA, Femto HS High Sensitivity, eBioscience), following the manufacturer's protocol. Cell-mediated lysis of indicated target cells was determined by standard 4.5 h chromium release assay as described (31) .
Analysis of mp68 RNA
RNA was isolated from indicated tumors and PCR analysis to detect expression of the wildtype or mutant p68 allele was done as described (23) .
Flow cytometry and antibodies
Erythrocytes in blood samples were lysed by ammonium chloride treatment. 
Longitudinal imaging
Implantation of windows, cancer cell injection, confocal microscopy and data analysis were done as described (29, 32) . Detailed information are provided in Supplementary Methods.
Results
'Reverse immunology' identifies a mutant epitope of p68 as neoantigen with high MHC affinity and broad expression in a genetically heterogeneous cancer. The 8101 tumor was induced by repeated exposure of a normal C57BL/6 mouse to UV light (24) . The tumor on the back of this mouse was excised along with heart and lung tissue to generate a strain of normal fibroblasts (HLF) (24) . Approximately 20 fragments of the autochthonous tumor 8101 were minced to generate an uncloned culture of 8101 cancer cells (23), herein after called "Bulk" (Fig. 1A ). This culture was only minimally expanded in vitro to provide cancer cells for sequencing and tumor induction in vivo.
Additional 20 fragments were kept for individual analysis to capture the spatial heterogeneity of mutations in the autochthonous tumor and to properly select a mutation as target for adoptive T cell therapy (ATT) that will likely be present in all parts of the tumor ( , was previously used to mark the common ancestry of the 8101 tumor (33) and was detected in all but 2 of the tumor fragments (Fig.   1D ).
The mp68 epitope, the immunodominant rejection antigen of the 8101 tumor, induces highavidity T cell clones. As reported above, algorithm analysis of exome and RNAseq data selected mp68
as highest ranking neoepitope. This is precisely the same neoepitope we had previously found to be the immunodominant rejection antigen in 8101 by direct immunology (24) . To obtain T cells recognizing this tumor-specific antigen, we generated a number of mp68-specific T cell clones from T cells of tumor-free mice that had been immunized with the uncloned 8101 cancer cells. Tumor-reactive T cells were expanded by repeated stimulation in vitro with irradiated 8101 tumor cells and subsequently cloned by limiting dilution. Fig. 1E shows that several clones achieved half maximal lysis of RMA-S cells at low peptide concentration (7.8 pM SNFVFAGI), while these T cells were not reactive against the corresponding p68 wild-type peptide (SNFVSAGI, specific lysis <10%, data not shown). These high avidities are in agreement with the previously determined EC 50 of another mp68-specific T cell clone (24) . Decisive for selecting 1D9 T cells as source of the TCR was the high reactivity against Bulk tumor cells expressing mp68 at natural levels (Fig. 1F) . Thus, we determined the 1D9 TCRα-and β-chain sequences and cloned them into a retrovirus vector ( Supplementary Fig. S3A ) for transduction of mice, which only express the OT-I-TCR specific for the ovalbumin peptide SIINFEKL, an irrelevant target for our model. Transduction efficacy was measured using TCRvβ6-specific antibodies (representative staining is shown in Supplementary Fig. S3C ). The specific lysis of Bulk tumor cells by 1D9td T cells ( Fig. 2A) was comparable to the lysis determined for the original 1D9 T cell clone (Fig. 1F) . (Fig. 2B) . The efficacy of 1D9tg and 1D9td T cells was similar. Whole exome sequencing of tumor reisolates (Reis#1, Reis#2) revealed a mutational pattern which was almost identical to the original Bulk tumor (Fig. 2C) . However, the variant allelic frequency (VAF) of mp68 seemed to be reduced (Fig. 2D, Supplementary Table S1 ). This reduction was apparently related to the escape from mp68-directed T cell therapy as the proportion of the p53 S238A mutation remained rather unchanged. Furthermore, Reis#1 and Reis#2 failed to express the mp68 RNA (Fig. 2E) . Fig. S4 ). 1D9td T cells recognized MC57-mp68 but not mock-transfected MC57 cells in standard cytotoxicity assays (Fig. 3A) . Remarkably, a single adoptive transfer of ~5x10 Fig. S5 ). Together, these data indicate that direct recognition of highly and uniformly expressed mp68 sufficed for the infused 1D9 T cells to localize to the solid tumor, find the cancer cells as stimulators to proliferate and to release sufficient amounts of cytokines to destroy the tumor vasculature and eradicate the cancer. Nevertheless, when the neoantigen was not cross-presented, cancer cell destruction was significantly delayed. Thus, stromal cross-presentation could become a determining factor for eradication of antigen-loss variants when the target antigen is not uniformly expressed by all cancer cells. This is suggested by previous experiments of adoptive therapy of tumors expressing surrogate antigens after transfection rather than transduction and containing significant numbers of antigen-negative cancer cells (see references in (36)). (Fig. 2B) . We then generated Bulk tumor cells that were transduced to express higher levels of mp68 antigen (Bulk-mp68, Supplementary Fig. S4B ). Bulk-mp68 tumor cells were killed effectively in vitro (Fig. 5B ) and stimulated ~20x higher IFN-γ release by 1D9 T cells ( 
Local tumor irradiation followed by adoptive T cell transfer reduces relapse of 8101 tumors
expressing the autochthonous mp68 antigen. We have previously shown that chemotherapeutic drugs or local irradiation can synergize with ATT to achieve eradication of cancers that fail to be rejected because they express too low levels of the targeted antigen (30) . The efficacy of the combined treatment correlated with antigen loading onto the stroma from cancer cells damaged or stressed by the chemo-or radiotherapy. We followed the same experimental design (30) induces acute inflammation that greatly helps the host (or experimentalist) to eradicate transplanted tumors at early stages (i.e. during the first two weeks after transplantation) (38) . When a tumor is targeted a month after transplantation, therapeutic procedures often become ineffective even when tumors remain rather small (39) . Therefore, it is important that TCR gene therapy described in this study eradicated tumors that were not only large (~1 cm in diameter) but had also been established for a month or longer.
Our studies of the 8101 tumor demonstrate that 'reverse immunology', the sequencing of a tumor's genetic information and the computational prediction of neoepitopes, predicts the neoantigen mp68 we had previously identified as immunodominant rejection antigen of 8101. While our study showed consistency between direct and 'reverse immunology', tracing of suitable neoepitopes without guidance by specific T cells can be misleading. For example, predicting the binding of cysteinecontaining peptides to MHC is problematic (40) and some neoepitopes predicted to bind may be destroyed by proteasomal cleavage (25) . Predicting neoepitopes in cancer by combining sequencing with mass spectometry analysis of eluted peptides (41) or multimer staining of specific T cells (12) could improve reliability.
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We suggest that the clinically relevant situation is likely to be mirrored by tumors composed of cancer cells expressing the tumor-specific mutations at natural levels, resembled by Bulk used in this study. Even though we targeted an immunodominant rejection antigen expressed in every analyzed part of the original tumor, previously unnoticed antigen-negative variants or cancer cells that lost antigen expression foiled cancer eradication by T cell therapy. We targeted a mutation in p68, a coactivator of p53 (1), which probably played a role as driver in the formation of the cancer but sustained expression was not required for tumor maintenance. Nevertheless, mp68 provided a subnanomolar affinity neoepitope expressed in comparison with other neoepitopes of the tumor at comparatively high levels.
Also, mp68 was found in all analyzed regions of the cancer, which suggested that this neoepitope was not affected by usual spatial tumor heterogeneity. Better targets would obviously be driver mutations essential for cancer cell function and survival and expressed at higher levels so that antigen escape does not occur (3, (42) (43) (44) . However, such ideal targets may be rare. Given the remarkable genetic and phenotypic diversity of cancers (45), we therefore believe that escape by antigen-negative variants will likely remain an important problem in targeting tumors, experimentally or clinically.
We propose several complementary solutions to solve the problem of escape from TCR gene therapy. First, targeting multiple independent neoepitopes on the same cancer could reduce the chance for therapy-induced selection of escape variants (26, 46) . For example, the 8101 primary cancer contained another neoepitope that was retained by mp68-loss variants and was recognized by a different clones. The T cell clone 1D9 is highlighted in red and was used for subsequent TCR isolation. 
